{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:02:17Z","timestamp":1776772937271,"version":"3.51.2"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["22K09390"],"award-info":[{"award-number":["22K09390"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["24K02574"],"award-info":[{"award-number":["24K02574"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-026-01372-6","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:33:09Z","timestamp":1776771189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Culture-dependent baseline states and drug response programs in myxofibrosarcoma models across 2D and 3D systems"],"prefix":"10.1007","volume":"39","author":[{"given":"Yuki","family":"Yoshimatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yomogi","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-7792","authenticated-orcid":false,"given":"Tadashi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"1372_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215132","author":"E Lucarelli","year":"2023","unstructured":"Lucarelli E, De Vita A, Bellotti C, et al. Modeling myxofibrosarcoma: where do we stand and what is missing? Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15215132.","journal-title":"Cancers"},{"key":"1372_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221093973","volume":"14","author":"S Vanni","year":"2022","unstructured":"Vanni S, De Vita A, Gurrieri L, et al. Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. Ther Adv Med Oncol. 2022;14:17588359221093973.","journal-title":"Ther Adv Med Oncol"},{"key":"1372_CR3","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol. 2021;32:1348\u201365.","journal-title":"Ann Oncol"},{"key":"1372_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415\u201323.","journal-title":"Lancet Oncol"},{"key":"1372_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.drudis.2012.10.003","volume":"18","author":"S Breslin","year":"2013","unstructured":"Breslin S, O\u2019Driscoll L. Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today. 2013;18:240\u20139.","journal-title":"Drug Discov Today"},{"key":"1372_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1407-3","volume":"19","author":"Y Sasagawa","year":"2018","unstructured":"Sasagawa Y, Danno H, Takada H, et al. Quartz-Seq2: a high-throughput single-cell RNA-sequencing method that effectively uses limited sequence reads. Genome Biol. 2018;19:29.","journal-title":"Genome Biol"},{"key":"1372_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.","journal-title":"BMC Bioinformatics"},{"key":"1372_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie Z, Bailey A, Kuleshov MV, et al. Gene Set knowledge discovery with Enrichr. Current protocols. 2021;1:e90.","journal-title":"Current protocols"},{"key":"1372_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"issue":"4","key":"1372_CR10","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1007\/s13577-021-00548-6","volume":"34","author":"R Tsuchiya","year":"2021","unstructured":"Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Sei A, Takeshita F, Sugaya J, Iwata S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34(4):1266\u201373. https:\/\/doi.org\/10.1007\/s13577-021-00548-6.","journal-title":"Hum Cell."},{"issue":"6","key":"1372_CR11","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s13577-021-00589-x","volume":"34","author":"Y Yoshimatsu","year":"2021","unstructured":"Yoshimatsu Y, Noguchi R, Tsuchiya R, Sin Y, Ono T, Sugaya J, Iwata S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34(6):1911\u20138. https:\/\/doi.org\/10.1007\/s13577-021-00589-x.","journal-title":"Hum Cell."},{"issue":"2","key":"1372_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/cells11020207","volume":"11","author":"R Tsuchiya","year":"2022","unstructured":"Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Sugaya J, Kobayashi E, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-MFS5-C1: a novel patient-derived cell line of myxofibrosarcoma. Cells. 2022;11(2):207. https:\/\/doi.org\/10.3390\/cells11020207.","journal-title":"Cells."},{"issue":"6","key":"1372_CR13","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s13577-022-00749-7","volume":"35","author":"Y Yoshimatsu","year":"2022","unstructured":"Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Akiyama T, Sato C, Kobayashi E, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-MFS6-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2022;35(6):1993\u20132001. https:\/\/doi.org\/10.1007\/s13577-022-00749-7.","journal-title":"Hum Cell."},{"issue":"6","key":"1372_CR14","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1007\/s13577-024-01124-4","volume":"37","author":"Y Adachi","year":"2024","unstructured":"Adachi Y, Noguchi R, Osaki J, Ono T, Iwata S, Akiyama T, Tsuchiya R, Toda Y, Sekita T, Iwata S, Kobayashi E, Kojima N, Yoshida A, Yokoo H, Kawai A, Kondo T. Establishment and characterization of two novel patient-derived cell lines frommyxofibrosarcoma: NCC-MFS7-C1 and NCC-MFS8-C1. Hum Cell. 2024;37(6):1742\u201350. https:\/\/doi.org\/10.1007\/s13577-024-01124-4.","journal-title":"Hum Cell."},{"key":"1372_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24086926","author":"S Vanni","year":"2023","unstructured":"Vanni S, Fausti V, Fonzi E, et al. Unveiling the genomic basis of chemosensitivity in sarcomas of the extremities: an integrated approach for an unmet clinical need. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24086926.","journal-title":"Int J Mol Sci"},{"key":"1372_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nrm1858","volume":"7","author":"LG Griffith","year":"2006","unstructured":"Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol. 2006;7:211\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1372_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrm2236","volume":"8","author":"F Pampaloni","year":"2007","unstructured":"Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8:839\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1372_CR18","first-page":"3015","volume":"125","author":"BM Baker","year":"2012","unstructured":"Baker BM, Chen CS. Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues. J Cell Sci. 2012;125:3015\u201324.","journal-title":"J Cell Sci"},{"key":"1372_CR19","first-page":"910","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska M, Kolenda T, Przyby\u0142a W, et al. 2D and 3D cell cultures\u2014a comparison of different types of cancer cell cultures. ARC Med Sci: AMS. 2018;14:910\u20139.","journal-title":"ARC Med Sci: AMS"},{"key":"1372_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/adt.2014.573","volume":"12","author":"R Edmondson","year":"2014","unstructured":"Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12:207\u201318.","journal-title":"Assay Drug Dev Technol"},{"key":"1372_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nprot.2008.226","volume":"4","author":"J Friedrich","year":"2009","unstructured":"Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009;4:309\u201324.","journal-title":"Nat Protoc"},{"key":"1372_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","volume":"148","author":"F Hirschhaeuser","year":"2010","unstructured":"Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010;148:3\u201315.","journal-title":"J Biotechnol"},{"key":"1372_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.2451290","volume":"240","author":"RM Sutherland","year":"1988","unstructured":"Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988;240:177\u201384.","journal-title":"Science"},{"key":"1372_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/09553000701727531","volume":"83","author":"J Friedrich","year":"2007","unstructured":"Friedrich J, Ebner R, Kunz-Schughart LA. Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge? Int J Radiat Biol. 2007;83:849\u201371.","journal-title":"Int J Radiat Biol"},{"key":"1372_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583\u201392.","journal-title":"Nat Rev Cancer"},{"key":"1372_CR26","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jnci\/djm135","volume":"99","author":"O Tr\u00e9dan","year":"2007","unstructured":"Tr\u00e9dan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441\u201354.","journal-title":"J Natl Cancer Inst"},{"key":"1372_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc2618","volume":"9","author":"JA Joyce","year":"2009","unstructured":"Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239\u201352.","journal-title":"Nat Rev Cancer"},{"key":"1372_CR28","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423\u201337.","journal-title":"Nat Med"},{"key":"1372_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nm.2328","volume":"17","author":"MJ Bissell","year":"2011","unstructured":"Bissell MJ, Hines WC. Why don\u2019t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17:320\u20139.","journal-title":"Nat Med"},{"key":"1372_CR30","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.15252\/embr.201439246","volume":"15","author":"MW Pickup","year":"2014","unstructured":"Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15:1243\u201353.","journal-title":"EMBO Rep"},{"key":"1372_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148:399\u2013408.","journal-title":"Cell"},{"key":"1372_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393\u2013410.","journal-title":"Nat Rev Cancer"},{"key":"1372_CR33","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"1372_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"1372_CR35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","volume":"132","author":"MS Hayden","year":"2008","unstructured":"Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344\u201362.","journal-title":"Cell"},{"key":"1372_CR36","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000141","volume":"1","author":"M Karin","year":"2009","unstructured":"Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009;1:a000141.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1372_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36\u201349.","journal-title":"Nat Rev Immunol"},{"key":"1372_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molcel.2015.01.023","volume":"58","author":"K Ichikawa","year":"2015","unstructured":"Ichikawa K, Kubota Y, Nakamura T, et al. MCRIP1, an ERK substrate, mediates ERK-induced gene silencing during epithelial-mesenchymal transition by regulating the co-repressor CtBP. Mol Cell. 2015;58:35\u201346.","journal-title":"Mol Cell"},{"key":"1372_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.diff.2023.100740","volume":"139","author":"M Biadun","year":"2024","unstructured":"Biadun M, Karelus R, Krowarsch D, Opalinski L, Zakrzewska M. FGF12: biology and function. Differentiation. 2024;139:100740.","journal-title":"Differentiation"},{"key":"1372_CR40","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","volume":"40","author":"J Fu","year":"2021","unstructured":"Fu J, Su X, Li Z, et al. HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene. 2021;40:4625\u201351.","journal-title":"Oncogene"},{"key":"1372_CR41","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0092-8674(03)00930-9","volume":"115","author":"L Hughes-Davies","year":"2003","unstructured":"Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell. 2003;115:523\u201335.","journal-title":"Cell"},{"key":"1372_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12935-021-01866-3","volume":"21","author":"D Tuluhong","year":"2021","unstructured":"Tuluhong D, Chen T, Wang J, et al. FZD2 promotes TGF-\u03b2-induced epithelial-to-mesenchymal transition in breast cancer via activating notch signaling pathway. Cancer Cell Int. 2021;21:199.","journal-title":"Cancer Cell Int"},{"key":"1372_CR43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1089\/ars.2009.2913","volume":"12","author":"LV Papp","year":"2010","unstructured":"Papp LV, Lu J, Bolderson E, et al. SECIS-binding protein 2 promotes cell survival by protecting against oxidative stress. Antioxid Redox Signal. 2010;12:797\u2013808.","journal-title":"Antioxid Redox Signal"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01372-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01372-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01372-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:33:10Z","timestamp":1776771190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01372-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1372"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01372-6","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no financial competing interests. Zeon BioSolutions Inc. provided RNA-seq services at no cost; the company had no role in study design, data interpretation, manuscript preparation, or the decision to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required because this study used established, publicly available patient-derived cell lines and did not involve identifiable human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"69"}}